PALI logo

PALI
Palisade Bio Inc

19,536
Mkt Cap
$317.65M
Volume
1.81M
52W High
$2.86
52W Low
$0.53
PE Ratio
-1.72
PALI Fundamentals
Price
$1.83
Prev Close
$1.81
Open
$1.80
50D MA
$2.00
Beta
0.97
Avg. Volume
4.41M
EPS (Annual)
-$0.3014
P/B
2.41
Rev/Employee
$0.00
$2.49
Loading...
Loading...
News
all
press releases
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Recommendation of "Moderate Buy" from Brokerages
Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) has received an average recommendation of 'Moderate Buy' from the eight analysts that are presently covering the firm, MarketBeat reports. One...
MarketBeat·12d ago
News Placeholder
More News
News Placeholder
Palisade Bio (PALI) Expected to Announce Earnings on Monday
Palisade Bio (NASDAQ:PALI) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-palisade-bio-inc-stock...
MarketBeat·13d ago
News Placeholder
These Stocks Could Rip into the Close
As the market barrels into the final hour of trading, momentum is clustering around a powerful trio of themes, AI infrastructure, next-gen materials, and sustainable agriculture. $KBLB, $LOCL, $MRVL, $POET, $PALI, $FFAI
24-7 Market News·26d ago
News Placeholder
Analysts Offer Predictions for Palisade Bio Q1 Earnings
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Investment analysts at Brookline Capital Markets issued their Q1 2026 earnings per share (EPS) estimates for Palisade Bio in a research note issued to...
MarketBeat·27d ago
News Placeholder
Brokers Issue Forecasts for Palisade Bio Q3 Earnings
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Stock analysts at Brookline Capital Markets issued their Q3 2026 EPS estimates for Palisade Bio in a research report issued on Wednesday, April 15th. Brookline Capital Markets analyst K. Raja expects that the company will earn ($0.06) per share for th...
MarketBeat·28d ago
News Placeholder
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Palisade Bio, Inc. (NASDAQ:PALI - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight brokerages that are covering the company, MarketBeat Ratings reports...
MarketBeat·1mo ago
News Placeholder
Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy
Wolfe Research upgraded shares of Palisade Bio to a "strong-buy" rating in a report on Wednesday...
MarketBeat·1mo ago
News Placeholder
Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI)
Wolfe Research assumed coverage on shares of Palisade Bio in a report on Thursday. They set an "outperform" rating and a $7.00 price objective for the company...
MarketBeat·1mo ago
News Placeholder
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn's Efficacy Signals
Palisade Bio (NASDAQ:PALI) said it generated encouraging safety, pharmacokinetic and early efficacy signals from an open-label Phase 1b study of PALI-2108 in fibrostenotic Crohn's disease, a difficult-to-treat population where patients often progress from inflammation to structural fibrosis and may...
MarketBeat·2mo ago
News Placeholder
HC Wainwright Forecasts Palisade Bio Q1 Earnings
Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Palisade Bio in a research report issued on...
MarketBeat·2mo ago
<
1
2
...
>

Latest PALI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.